Brief: Compass Therapeutics Announces First Patient Dosed In Phase 1 Study Of CTX-8371
16/04/2024 13:28
April 16 (Reuters) - Compass Therapeutics Inc. CMPX.O :
* COMPASS THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE
PHASE
1 STUDY OF CTX-8371 IN PATIENTS WITH SOLID TUMORS
Source text for Eikon: ID:nGNX5RJfHV
Further company coverage: CMPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback